A Double-blind, Randomized, Sham-procedure-controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP41750) in Patients withChronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Non-ischemic Etiology
Cell therapy for patients with heart failure
Sponsor: Teva Pharmaceutical Industries
Enrolling: Male and Female Patients
IRB Number: AAAO3307
U.S. Govt. ID: NCT02032004
Contact: Danielle Brunjes - Mary Marks: 212-305-1429 / dlt2127@cumc.columbia.edu
Additional Study Information: This research study will evaluate the effectiveness of CEP-417 (Mesenchymal Precursor Cells (MPCs)) when administered through an injection catheter to your heart muscle improving your symptoms, helping your heart function better, improving your quality of life, and in reducing the number of times you may need to be hospitalized due to your heart failure. These cells are special cells that were obtained from the bone marrow of a healthy person or donor who donated bone marrow for the purpose of this study. The donor was tested carefully for many diseases to minimize the possibility that a disease would be passed on to you, the recipient. The cells were isolated from the healthy person bone marrow, further purified and then grown outside the donor's body in order to increase the number of cells.
This study is closed
Paul Schulze, MD
Do You Qualify?
Have you been diagnosed with chronic heart failure for at least 6 months? Yes No
Are you 18 to 80 years of age? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Danielle Brunjes - Mary Marks